Frontlight ResearchEarly access
Taking people in BelgiumPhase 1
Testing a Targeted Medicine in Adults With Rheumatoid Arthritis
Tests a targeted medicine in adults with rheumatoid arthritis, a joint disease.
Key facts
- Who runs it
- AbbVie Deutschland GmbH & Co. KG
- Where
- Gent, BelgiumSee the siteAlso in 4 other countries, 12 sites
- Trial code
- Registry title
- A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 19 people, planned
- Started
- 17 Jul 2026
- Expected to end
- 25 Jan 2029
- Type of study
- Interventional
- Record updated
- 1 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rheumatoid arthritis. It studies targeted therapies.
- Age
- 18 years or older
- Sex
- Men and women can join
Main reasons for not taking part
- Healthy volunteers cannot join
Where in Belgium
Also in 4 other countries, 12 sites
- Universitair Ziekenhuis GentGent, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Testing a Targeted Medicine in Adults With Rheumatoid ArthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 1 September 2026